Overview

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Status:
Completed
Trial end date:
2021-08-30
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AbbVie
Criteria
Inclusion Criteria:

- Diagnosis of primary-progressive multiple sclerosis (PPMS) or non-relapsing
secondary-progressive multiple sclerosis (SPMS) and no relapses for at least 24
months.

- Evidence of physical disability according to Expanded Disability Status Scale (EDSS)
or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test.

Exclusion Criteria:

- Treatment with any of the following within the 6 months prior to Screening:
natalizumab; cyclosporine; azathioprine; methotrexate; mycophenolate mofetil;
intravenous immunoglobulin (IVIg); any interferon product; and intravenous (IV), oral,
or intrathecal corticosteroids for the purposes of disease modification.

- Treatment with the following within 1 year prior to Screening: cyclophosphamide or
alemtuzumab.